Gaining an Enhanced Understanding of HER2 Expression in Breast Cancer

Advancements in Oncology panelist Dr. Margaret Gatti-Mays continues her post-panel discussion as she delves into the topic of HER2 tumor expression. She also detailed the DESTINY Breast-06 study that was presented at the 2024 American Society of Clinical Oncology Annual Meeting. The study found that patients with HER2-low and HER2-ultra-low expression can benefit from treatment with newer antibody-drug conjugates.